Top Losartan Brands for Reliable Hypertension Management

Losartan, a popular medication used to treat high blood pressure and protect the kidneys from damage due to diabetes, has numerous brands available worldwide. Patients and healthcare providers often seek reputable and high-quality brands to ensure safety and efficacy. Some of the top brands that have gained trust and recognition in the market include Cozaar, the original brand by Merck; Losacar, known for its affordability and reliability; Losar, which is favored in various international markets for its consistent results; and LoZide, praised for its patient-friendly formulas. Curious to explore these brands further and learn about additional options? Check out the comprehensive list and insights below.

Illustration of losartan

Best brands of losartan in 2025

Cozaar

Cozaar, a brand of losartan potassium by Merck, is a leading angiotensin II receptor blocker used primarily to treat hypertension and other cardiovascular conditions. The global losartan market, which includes Cozaar, is projected to expand from USD 1.5 billion in 2023 to USD 2.3 billion by 2034, growing at a CAGR of 4%. In 2024, the global losartan market size is estimated at USD 1625.5 million, with North America holding over 40% of the global revenue. Cozaar is available in tablets of 25 mg, 50 mg, and 100 mg, and its market dominance is supported by the well-established healthcare infrastructure in regions like North America. The increasing prevalence of hypertension worldwide drives the market's significant growth.

Losartan by Teva Pharmaceuticals

Teva Pharmaceuticals is a leading producer of Losartan, a medication belonging to the angiotensin II receptor blockers (ARBs) class, used to treat hypertension and certain heart conditions. The global Losartan market, which includes Teva's products, is projected to grow at a CAGR of 4.5% from 2024 to 2031, reaching a market size of USD 2212.1 million by 2031. In 2024, the North American market, where Teva is a significant player, held over 40% of the global revenue with a market size of USD 650.2 million. Despite recalls due to impurities, such as the 2019 recall of Losartan Potassium tablets by Teva, the company remains committed to patient safety and product quality. Teva's Losartan is available in various dosages, including 25 mg, 50 mg, and 100 mg tablets.

Losartan by Torrent Pharmaceuticals

Losartan, particularly the version produced by Torrent Pharmaceuticals, is a highly regarded angiotensin II receptor blocker (ARB) used to treat hypertension, diabetic nephropathy, and reduce the risk of stroke. The global losartan market, which includes products from Torrent Pharmaceuticals, is projected to expand to USD 2.3 billion by 2034, growing at a CAGR of 4% from 2024 to 2034. In 2024, the global losartan market size was estimated at USD 1625.5 million, with North America holding over 40% of the global revenue, driven by the prevalence of hypertension and well-established healthcare infrastructure. Losartan's effectiveness and the trust in brands like Torrent Pharmaceuticals are crucial, especially given past recalls of contaminated ARBs, which highlighted the importance of quality manufacturing. The market's growth is also fueled by increasing awareness of cardiovascular health and the availability of healthcare services.

Losartan by Sandoz

Losartan, marketed by Sandoz (a division of Novartis), is a leading angiotensin II receptor antagonist used to treat high blood pressure and protect kidneys from damage due to diabetes. It was first approved by the FDA in 1995 and has since become one of the most prescribed drugs in its class, with over 47 million prescriptions in the US in 2020. Losartan accounts for nearly 20% of all ARB prescriptions in the US, highlighting its widespread use. The generic version of losartan potassium hydrochlorothiazide tablets, which Sandoz produces, dominates the market with over 80% of the revenue, driven by its affordability and accessibility. For more detailed information, visit the Sandoz Losartan product page.

Losartan by Mylan Pharmaceuticals

The Losartan market, dominated by tablets with a market share of nearly 87%, is driven by the growing prevalence of hypertension and diabetic nephropathy, with the global market valued at $4.73 billion in 2020 and expected to grow at a CAGR of 7.81% until 2026. Mylan Pharmaceuticals, as a key player, contributes significantly to this growth, particularly through in-house manufacturing which is expected to witness the fastest growth due to increased preference for quality control. North America, with its well-established healthcare infrastructure, leads the market, while Asia-Pacific is anticipated to see robust growth. The offline distribution channel remains dominant, although online channels are gaining traction. Generic versions, including those from Mylan, account for over 80% of the market revenue, enhancing affordability and accessibility.

Losartan by Aurobindo Pharma

Aurobindo Pharma is a prominent player in the losartan market, known for its high-quality losartan products. The global losartan market, valued at USD 1625.5 million in 2024, is expected to grow at a CAGR of 4.50% from 2024 to 2031, with North America holding over 40% of the global revenue. Aurobindo Pharma, along with other key players like Merck & Co., Inc. and Teva Pharmaceutical Industries Ltd., contributes significantly to this growth. The company's losartan products are widely used for treating hypertension and certain heart conditions, leveraging the drug's mechanism as an angiotensin II receptor blocker (ARB).

Losartan by Lupin Pharmaceuticals

Lupin Pharmaceuticals is a prominent producer of Losartan, a widely used angiotensin II receptor blocker for treating hypertension and other cardiovascular conditions. The global Losartan market, which includes Lupin's offerings, is projected to expand from USD 1.5 billion in 2023 to USD 2.3 billion by 2034, growing at a CAGR of 4% from 2024 to 2034. In 2024, the global Losartan market size is estimated at USD 1625.5 million, with North America holding over 40% of the global revenue. Lupin's Losartan products are available in various forms, with tablets dominating the market share at nearly 87%. The increasing prevalence of hypertension, particularly among aging populations, drives the demand for Losartan. For more details, visit Lupin's Losartan Potassium Tablets page.

Losartan by Sun Pharmaceuticals

Losartan, a medication used to treat high blood pressure and certain heart conditions, is effectively produced by various pharmaceutical companies, including Sun Pharmaceuticals. The global Losartan market, valued at USD 1625.5 million in 2024, is expected to grow at a CAGR of 4.50% from 2024 to 2031. North America, with a market size of USD 650.2 million in 2024, holds a significant share, while the Asia-Pacific region is anticipated to witness robust growth due to a large patient pool. Losartan, an angiotensin II receptor blocker (ARB), dominates the market in tablet form, with nearly 87% market share. Sun Pharmaceuticals, as a major producer, contributes to the market's growth through its high-quality and widely distributed products. For more details, visit their Losartan product page.

Losartan by Zydus Pharmaceuticals

Losartan, produced by Zydus Pharmaceuticals, is a highly effective angiotensin receptor blocker used to treat hypertension, reduce the risk of stroke, and manage diabetic nephropathy. Zydus, one of the top pharmaceutical companies in India, began registering generic versions of losartan in 2002, with multiple registrations in subsequent years, contributing significantly to the market share. By 2010, losartan experienced a notable increase in market share, particularly after its inclusion in the Farmacia Popular Program in Brazil, where it represented a significant portion of government expenditures. Zydus's losartan formulations are bioequivalent and therapeutically equivalent to the reference listed drug, ensuring high quality and efficacy. The company's strong presence in the pharmaceutical market, with a domestic market share of 3.9%, underscores its reliability as a producer of losartan. For more information about their products, visit Zydus Pharmaceuticals.

Losartan by Apotex Inc.

Apotex Inc. is a significant producer of Losartan, a widely used angiotensin receptor blocker (ARB) for treating high blood pressure and heart conditions. Despite facing challenges, including the voluntary recall of Losartan products due to potential nitrosamine impurities in 2019, Apotex has been a major player in the global Losartan market. The global Losartan API market, valued at USD 1652.2 million in 2024, sees North America holding over 40% of the market share, a region where Apotex has a strong presence. However, manufacturing deficiencies at Apotex's India-based plants led to the FDA approving the voluntary withdrawal of 31 generic drug approvals, including Losartan, in 2019. Apotex's products were among those recalled in Canada and internationally due to these impurities. For more information, visit the Health Canada website.